Analyst Price Targets — RNAC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 9, 2026 2:57 pm | — | Cantor Fitzgerald | $16.00 | $9.02 | TheFly | Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald |
| August 9, 2024 6:19 am | Mitchell Kapoor | H.C. Wainwright | $45.00 | $12.87 | TheFly | Cartesian Therapeutics price target lowered to $45 from $49 at H.C. Wainwright |
| July 3, 2024 7:55 am | John Newman | Canaccord Genuity | $43.00 | $15.77 | TheFly | Cartesian Therapeutics price target raised to $43 from $38 at Canaccord |
| May 24, 2024 5:35 am | Uy Ear | Mizuho Securities | $40.00 | $25.46 | StreetInsider | Mizuho Resumes Cartesian Therapeutics (RNAC) at Buy |
Latest News for RNAC
Cartesian Therapeutics, Inc. (RNAC) came out with a quarterly loss of $1.46 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $0.68 per share a year ago.
Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome initiated Multiple patients enrolled in Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis Approximately $120.4 million cash, cash equivalents and restricted cash as of March 31, 2026 , expected to support planned…
Cartesian Therapeutics receives a buy rating, driven by a differentiated mRNA CAR-T approach for autoimmune diseases and strong insider/institutional support. RNAC's lead asset, Descartes-08, demonstrated a 7.1-point MG-ADL reduction at 12 months in Phase 2b, surpassing current biologics in durability and efficacy. The ongoing Phase 3 AURORA trial, with FDA SPA agreement and 100 patients, is a pivotal binary…
Cartesian Therapeutics, Inc. (RNAC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Cartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RNAC.
U.S. House Trading
No House trades found for RNAC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.